NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
TORONTO, ON / ACCESS Newswire / July 15, 2026 / Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF)(CSE:RVV)(FRANKFURT:31R), a life sciences company focused on infectious diseases and medical countermeasures, announces that it has closed the first tranche of its previously announced non-brokered private placement for gross proceeds of $246,920 (the "Private Placement").
The Private Placement consisted of the issuance and sale of 7,716,250 units of the Company ("Units"), at a price of $0.032 per Unit. Each Unit issued pursuant to the Private Placement consists of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant will entitle the holder to acquire one Common Share at an exercise price of $0.05 for a period of 36 months following the closing date of the Private Placement.
The Company intends to use the gross proceeds from the Private Placement primarily for working capital purposes.
In connection with the first tranche closing, the Company has also paid certain finders an aggregate of $17,433.60 and issued an aggregate of 537,300 broker warrants to purchase Common Shares (the "Broker Warrants"). Each Broker Warrant will entitle the holder to purchase one Common Share at an exercise price equal to $0.05 for a period of 36 months following the closing of the Private Placement.
The Company will provide an update on any further closings under the Private Placement.
All of the securities will be subject to a hold period of four months and one day from the date of issuance.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures. Revive prioritizes its drug-development efforts to take advantage of regulatory incentives that may be available for important unmet medical needs. The Company is currently exploring the use of bucillamine for infectious diseases, nerve agent exposure and long COVID, among other potential applications. For more information, visit www.ReviveThera.com.
For more information, please contact:
Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the CSE nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement